Natural Products
- ChemFaces is a professional high-purity natural products manufacturer.
- Product Intended Use
- 1. Reference standards
- 2. Pharmacological research
- 3. Inhibitors
| Size /Price /Stock | 10 mM * 1 mL in DMSO / Inquiry | Other Packaging | *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap |
| Size /Price /Stock | 10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock | Related Libraries |
| Description: | 1. Neosarracine and sarracine show immunomodulatory activities. |
| Targets: | Immunology & Inflammation related |
| Source: | The herbs of Senecio scandens |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| Storage: | Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com |
| After receiving: | The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling. |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9638 mL | 14.8188 mL | 29.6375 mL | 59.2751 mL | 74.0938 mL |
| 5 mM | 0.5928 mL | 2.9638 mL | 5.9275 mL | 11.855 mL | 14.8188 mL |
| 10 mM | 0.2964 mL | 1.4819 mL | 2.9638 mL | 5.9275 mL | 7.4094 mL |
| 50 mM | 0.0593 mL | 0.2964 mL | 0.5928 mL | 1.1855 mL | 1.4819 mL |
| 100 mM | 0.0296 mL | 0.1482 mL | 0.2964 mL | 0.5928 mL | 0.7409 mL |
| Citation [1] Rhodes University,1996 | The pyrrolizidine alkaloids of Senecio chrysocoma and Senecio paniculatus[Reference: WebLink] |
| In order to compare the pyrrolizidine alkaloid content of two closely related species, Senecio chrysocoma and S. paniculatus, nine populations of plants distributed between the two species, were examined. Three novel pyrrolizidine alkaloids, 7ß-angelyl-l-methylene-8∝-pyrrolizidine, 7ß-angelyl-l-methylene-8∝-pyrrolizidine and 7ß-angelyl-l-methyleneSO!-pyrrolizidine-4-oxide, as well as eight known pyrrolizidine alkaloids, 7-angelylhastanecine, 9-angelylhastanecine, 7-angelylplatynecine, 9-angelylplatynecine, 9-angelylplatynecine-4-oxide, sarracine, Neosarracine and retrorsine, were isolated and identified by NMR and GC-MS techniques. Traces of five tiglyl isomers, 9-tiglylplatynecine, 9-tigl ylplatynecine-4-oxide, 7ß-tiglyl-l-methylene-8∝-pyrrolizidine, sarranicine and Neosarranicine, were also isolated and tentatively identified; however, these compounds could have been artefacts of the extraction and analytical procedures. | |
| Citation [2] Acta morphologica et anthropologica,2004,9. | Immunomodulatory activities of Pyrrolizidine alkaloids Sarracine and NeoSarracine isolated from Senecio macedonicus[Reference: WebLink] |
| Immunomodulatory activities of Pyrrolizidine alkaloids Sarracine and Neosarracine isolated from Senecio macedonicus |
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)